Gut microbiome modulation through non-pharmacological therapy in psychiatric disorders: neurotransmitter synthesis, neuroplasticity, and brain-gut signaling

Psychiatric disorders affect over 970 million people globally, with substantial personal, social, and economic costs that continue to rise despite advances in treatment. Current pharmacological approaches show limited efficacy for many patients, with significant side effects and high discontinuation rates. The integration of microbiome science with psychiatric research offers new perspectives on disease etiology, biomarker development, and therapeutic intervention. Recent advances in microbiome research reveal that the gut microbiome directly synthesizes neurotransmitters and their precursors, while microbial metabolites produced by the microorganisms through their metabolic activities, cross the blood-brain barrier (BBB) to influence regulate microglial activation, synaptic plasticity, neurogenesis, and neural circuit development associated with our brain’s function. Specific gut bacterial taxa demonstrate causal relationships with psychiatric symptoms through vagal, immune, and metabolic pathways. Gut dysbiosis patterns consistently emerge across major psychiatric conditions associated with distinct microbial signatures. Scientific research has discovered that disrupted circadian rhythm and dysregulated stress response system especially the hypothalamic pituitary adrenal (HPA) axis both disrupt gut microbiota composition and function, leading to health issues like metabolic syndrome, gastrointestinal disorders, and mental wellness issues. Understanding these mechanisms opens unprecedented opportunities for non-pharmacological approaches that integrate microbiome analysis and targeted interventions. The authors of this article aim to explore how non-pharmacological intervention methods such as mental wellness behavioral therapy and educational therapy can be integrated with gut microbiome knowledge to enhance patient outcomes, focusing on mental health, gastrointestinal, and metabolic disorders.